Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry

The aim was to evaluate quality of life (QoL), pain, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with different regimens after first-line docetaxel, as well as disease progression.

Patients with mCRPC having received first-line chemotherapy with docetaxel were eligible. Second-line treatment choice was at the discretion of the local investigator. All patients had regular assessments of QoL with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, of fatigue with the Brief Fatigue Inventory, and of pain with the McGill Pain Questionnaire-Short Form. The primary end point was QoL maintenance defined as having a maximum decrease in 2 functional domains of the FACT-P.

One hundred thirty-eight patients were included in 36 oncology centers across Switzerland. QoL analysis was available for all patients (59 who received cabazitaxel; 79 who received other therapy [OT] including 75 who received abiraterone). No significant differences for any of the end points were found between groups. A numerically higher number of patients had QoL maintenance with OT (25 of 79 patients, 32%) compared with cabazitaxel (8 of 59 patients, 14%). QoL improvement was found in 20% of patients (12 of 59) who received cabazitaxel and 24% (19 of 79) who received OT. Mean FACT-P score did not change in a clinically relevant manner over time in either group. Pain was present in 70% of patients (96 of 138), and a pain response to treatment was noted in 22% (13 of 59) who received cabazitaxel and 29% (23 of 79) who received OT. A similar but minor improvement of fatigue was noted in both groups.

Some degree of QoL decrease was seen in most patients regardless of second-line treatment. No significant differences in QoL parameters between cabazitaxel or other second line treatments were found.

Clinical genitourinary cancer. 2017 Aug 24 [Epub ahead of print]

Frank Stenner, Sacha I Rothschild, Daniel Betticher, Clemens Caspar, Rudolf Morant, Razvan Popescu, Daniel Rauch, Urs Huber, Reinhard Zenhäusern, Cyrill Rentsch, Richard Cathomas

Department of Oncology, University Hospital Basel, Basel, Switzerland., Department of Oncology, Cantonal Hospital, Fribourg, Switzerland., Department of Oncology, Cantonal Hospital, Baden, Switzerland., Center for Tumors and Prevention ZeTuP, Rapperswil-Jona, Switzerland., Division of Oncology, Hirslanden Medical Center, Aarau, Switzerland., Division of Oncology, Hospital Thun, Thun, Switzerland., Oncology Center, Hirslanden Clinic, Zürich, Switzerland., Division of Oncology, Hospital Oberwallis, Brig, Switzerland., Department of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland. Electronic address: .